Autoimmune Hepatitis with Anti Centromere Antibodies

Lodh, Moushumi; Pradhan, Debkant; Parida, Ashok

doi:10.1155/2013/742080

Cited by 3 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They informed that laboratory investigations provided diagnosis of AIH with anticentromere antibodies. The authors reported that screening AIH patients for anticentromere antibody is not obligatory, however, can be regarded, particularly in the presence of disease-related symptomatology for quicker, more reliable diagnosis and optimum management (10). The Committee for Autoimmune Serology of the International Autoimmune Hepatitis Group (IAIHG) supplied guidelines on testing for autoantibodies associated with AIH.…”

Section: Discussionmentioning

confidence: 99%

Investigation of liver autoantibodies in anticentromere antibody positive patients: A preliminary research

Şener¹,

Bugdacý²,

Yula³

et al. 2016

J Immunol Clin Microbiol

View full text Add to dashboard Cite

In the present study, anti-soluble liver antigen\liver pancreas antigen (anti-SLA\LP), anti-liver cytosolic antigen 1 (anti-LC1), anti-liver kidney microsomal antigen 1 (anti-LKM1), and anti-mitochondrial antibody M2 (AMA-M2) were evaluated in the patients who had positive anticentromere antibody. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License(http://creativecommons.org/licenses/bync/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. AbstractBackground: Anticentromere antibody (ACA) is regarded to be a serological marker specific to CREST (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactylia, and telangiectasia) syndrome. ACA is also found in the sera of patients with autoimmune liver disease. In the present work, anti-soluble liver antigen\liver pancreas antigen (anti-SLA\LP), anti-liver cytosolic antigen 1 (anti-LC1), anti-liver kidney microsomal antigen 1 (anti-LKM1), and antimitochondrial antibody M2 (AMA-M2) were evaluated in the patients who had positive anticentromere antibody. Material and Methods: A total of 39 patients who were positive anticentromere antibody were enrolled in this study undertaken in the Izmir Katip Celebi University, Ataturk Training and Research Hospital, Microbiology laboratory between January and September 2015. Positive anticentromere antibody and liver autoantibodies were analyzed. Anticentromere antibody and liver autoantibodies were studied by indirect immunofluorescence method (IIF) and immunoblotting method (IB), respectively. The patients who had negative anticentromere antibody were used as a control group. Results: According to the study's results, positivity was detected in 3 of 39 patients (%7.6) in terms of liver autoantibodies, all of which were AMA-M2. There was no statistically significant difference between ACA and autoimmune liver autoantibodies. Conclusion: In this study, we reported our preliminary experience to provide evidence for the detection of various autoantibodies as potential diagnostic or prognostic tests. Further studies that contain a broad range of patients may contribute to the field.

show abstract

Section: Discussionmentioning

confidence: 99%

Investigation of liver autoantibodies in anticentromere antibody positive patients: A preliminary research

Şener¹,

Bugdacý²,

Yula³

et al. 2016

J Immunol Clin Microbiol

View full text Add to dashboard Cite

show abstract

“…Of note, among the remaining ten patients, four patients had AIH, two patients had PBC, and four patients had AIH-PBC overlap syndrome. As only a few reports have suggested an association between the presence of anti-centromere antibodies and AILD, future studies are warranted to investigate the role of anticentromere antibodies in AILD [29][30][31].…”

Section: Plos Onementioning

confidence: 99%

The significance of cytoplasmic antinuclear antibody patterns in autoimmune liver disease

et al. 2021

View full text Add to dashboard Cite

We aimed to determine the significance of cytoplasmic antinuclear antibody (ANA) patterns using computer-aided immunofluorescence microscopy in patients with autoimmune liver diseases (AILD). ANA staining pattern was identified by treating cultured human epithelial type 2 (HEp-2) cells with the sera of the patients. Medical records of patients with suspected AILD who had positive cytoplasmic ANA patterns between February 2017 and November 2019 were retrospectively reviewed for clinical, laboratory, and immunological data. Cytoplasmic ANA patterns of AILD and non-AILD groups were compared. Further subgroup analysis of patients with AILD who had reticular or speckled cytoplasmic ANA patterns was conducted. We found that among the 196 patients with positive cytoplasmic ANA patterns, 113 (57.6%) were diagnosed with AILD. The percentage of reticular cytoplasmic pattern was higher in the AILD group than that in the non-AILD group (64.0% vs. 21.9%, p < 0.001). Furthermore, patients with AILD who exhibited a reticular ANA pattern demonstrated a higher positive rate for anti-mitochondrial antibodies (66.7% vs. 2.6%, p < 0.001) than those who exhibited the speckled ANA pattern. Moreover, AILD patients with the reticular ANA pattern displayed a lower positive rate for anti-smooth muscle antibodies (0% vs. 45%, p < 0.001) and nuclear ANA pattern (73.2% vs. 97.5%, p = 0.003) than those with the speckled ANA pattern. Therefore, cytoplasmic ANA patterns could be used to guide AILD characterization in suspected AILD cases, especially as the reticular ANA pattern is strongly associated with AILD. Thus, it is important to check cytoplasmic ANA patterns for AILD evaluation, even when nuclear ANA patterns are negative.

show abstract